Vivus (VVUS +8.2%) pops despite posting a Q1 miss as sales of its weight-loss drug Qsymia came in lighter than analysts' expectations. The company wrote off $5.77M due to expired inventory, making it glaringly apparent that Qsymia's launch isn't going as planned. However, in its call, CEO Leland Wilson commented that the company is beginning discussions with large pharmaceutical companies in order to "significantly expand commercialization efforts." Wilson says VVUS has a target of mid-July to bring Qsymia into retail pharmacies. Read more on its earnings call here: Earnings Call Transcript.